NCT05463796

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

RecruitingOBSERVATIONAL

Trial Details

Start: 2023-04-25Est. Completion: 2030-03-25

Enrollment target: 5,000 participants

Locations

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Contact

Jenna Beckwith, MPHinadvancestudy@dfci.harvard.edu 857-215-1892

Tia Kauffman, MPH

Other microbiome trials you might be interested in

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerPhase 2Recruiting

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaStage II Laryngeal Cancer AJCC v8Stage II Lip and Oral Cavity Cancer AJCC v8Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.